Kathleen Mullin
Neurology · Stamford, CTNPI 1740428317
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Lilly USA, LLC at 37.4% of the total. Reporting peaked in 2019 at $53,543 and has fallen 67.4% since, to $17,455 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,587 payments — averaging $149.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$89K
- AbbVie$32K
- Pfizer$31K
- Amgen$20K
- Teva Pharmaceuticals USA, Inc.$19K
- Biohaven Pharmaceuticals, Inc.$12K
- plus $34K from 54 others
Across 90 payments — averaging $10,300 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceuticals, Inc.$424K
- H. Lundbeck A S$247K
- Pfizer$131K
- Biohaven Pharmaceutical Holding Company Ltd.$126K
What the payments were for
- Consulting fees$63,37527%
- Speaking & faculty fees$135,47957%
- Grants$850%
- Travel & lodging$11,3615%
- Food & beverage$26,87911%
- Education$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$237,338 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 14 | $27,734 |
| Emgality PenGalcanezumab-Gnlm | 17 | $11,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $31,363 | $27,73414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 280 neurology providers in Connecticut.
Other neurology in Stamford
- Stewart TepperStamford$1.2M
- Eric KungStamford$83K
- Olivia Begasse de DhaemStamford$32K
- Charisse LitchmanStamford$23K
- Peter McAllisterFairfield$2.3M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.